Daré Bioscience Launches DARE to PLAY Cream, Eyes Q2 2026 Revenue
Daré Bioscience’s DARE to PLAY topical sildenafil cream, manufactured under cGMP and shown to boost genital blood flow within 10 minutes, launched via Section 503B compounding with prescriptions now available nationwide and telehealth access. The company anticipates first product revenue in Q2 2026 while pursuing a 505(b)(2) NDA.
1. Full-Year 2025 Results and Business Update
Daré Bioscience reported its financial results for the year ended December 31, 2025, and hosted a conference call to outline multiple near-term catalysts, emphasizing the upcoming first product revenue in Q2 2026 and ongoing progress across its women’s health portfolio.
2. Commercial Launch of DARE to PLAY Cream
DARE to PLAY is the first cGMP-manufactured topical sildenafil cream studied in women, shown to increase genital blood flow within 10 minutes and improve arousal endpoints. Prescription intake began in December 2025 via Section 503B compounding, with pre-fulfillment expanded to all 50 states and telehealth prescribing launched in February 2026, as dispensing is set to start in the coming months while the company advances a 505(b)(2) NDA.
3. Pipeline Expansion with DARE to RESTORE and RECLAIM
The DARE to RESTORE line will introduce Flora Sync LF5 vaginal probiotic suppositories in Q2 2026 through the DARE Health Hub, backed by a 100-person clinical trial and exclusive LF5 probiotic strain. DARE to RECLAIM, a combined bioidentical estradiol-progesterone intravaginal ring targeting a $2.5–4.5 billion market, is slated for early 2027 prescription fulfillment with parallel IND-enabling activities.